-
Haisco Pharmaceutical’s HSK44459 Receives NMPA Approval for Psoriasis and Atopic Dermatitis Trials
•
China-based Haisco Pharmaceutical Group Co., Ltd (SHE: 002653) announced receiving approval from the National Medical Products Administration (NMPA) to initiate clinical studies for its Category 1 chemical drug HSK44459. The drug will be assessed for use in treating psoriasis and atopic dermatitis (AD), chronic, recurrent, and immune-inflammatory skin diseases with…
-
Haisco Pharmaceutical Group Registers Delaware Subsidiary to Expand Global Operations
•
Shenzhen-based Haisco Pharmaceutical Group Co., Ltd (SHE: 002653) has announced the registration of a new business in Delaware, United States. The company has established a USD 50,000 subsidiary named Hexgen Pharmaceutical Holding Limited, marking its latest move to accelerate global expansion and enhance its core competitiveness on an international scale.…
-
Haisco’s HSK39004 Gains NMPA Approval for COPD Clinical Trials
•
China-based Haisco Pharmaceutical Group Co., Ltd (SHE: 002653) announced that it has received clinical trial approval from the National Medical Products Administration (NMPA) for its HSK39004. The targeted small molecule inhibitor is now cleared to be assessed in clinical trials for chronic obstructive pulmonary disease (COPD), marking a significant step…
-
Haisco’s HSK44459 Approved for Clinical Trials in Behcet’s Disease
•
China-based Haisco Pharmaceutical Group Co., Ltd (SHE: 002653) has announced receiving clinical trial approval from the National Medical Products Administration (NMPA) for its investigational product HSK44459 in Behcet’s disease. This rare disease is listed in China’s second catalogue of rare diseases, highlighting the significant unmet medical need it represents. Behcet’s…
-
Haisco Pharmaceutical’s HSK46575 Receives NMPA Approval for Prostate Cancer Clinical Trial
•
China-based Haisco Pharmaceutical Group Co., Ltd (SHE: 002653) has announced the receipt of clinical trial approval from the National Medical Products Administration (NMPA) for its Category 1 chemical drug HSK46575, which is intended for the treatment of prostate cancer. HSK46575: A Promising Oral Small Molecule InhibitorHSK46575 has demonstrated significant therapeutic…
-
Haisco Pharmaceutical’s HSK21542 for Itching in Dialysis Patients Receives NMPA Review
•
Haisco Pharmaceutical Group Co., Ltd (SHE: 002653), a prominent Chinese pharmaceutical company, has announced that its marketing application for HSK21542, a Category 1 drug, has been accepted for review by the National Medical Products Administration (NMPA). The drug is intended for the treatment of moderate to severe itching associated with…
-
Haisco Pharmaceutical’s PDE4B Inhibitor HSK44459 Gets NMPA Green Light for Interstitial Lung Disease Clinical Trial
•
Haisco Pharmaceutical Group Co., Ltd (SHE: 002653), a Chinese pharmaceutical company, has announced that it has obtained clinical trial approval from the National Medical Products Administration (NMPA) for its Category 1 chemical drug HSK44459. This phosphodiesterase 4B (PDE4B) inhibitor is now set to be evaluated for its efficacy in treating…
-
Haisco Pharmaceutical’s Crisugabalin Gains NMPA Approval for Post-Herpes Neuralgia Treatment
•
Haisco Pharmaceutical Group Co., Ltd (SHE: 002653), a leading pharmaceutical company based in China, has announced that the National Medical Products Administration (NMPA) has approved an additional market approval filing for its drug candidate crisugabalin (HSK16149). This latest approval expands the drug’s indication to include the treatment of post-herpetic neuralgia…
-
Haisco Pharmaceutical Gets NMPA Green Light for Cofrogliptin to Treat Type 2 Diabetes
•
Haisco Pharmaceutical Group Co., Ltd (SHE: 002653) has announced that it has received marketing approval from the National Medical Products Administration (NMPA) for its Category 1 drug cofrogliptin (HSK7653), a long-acting dipeptidyl peptidase-4 (DPP-4) inhibitor. The drug is now approved for use in improving blood sugar control in patients with…
-
Haisco Pharmaceutical’s BRAF Inhibitor HSK42360 Gains NMPA Approval for Clinical Trials
•
Haisco Pharmaceutical Group Co., Ltd (SHE: 002653), a leading pharmaceutical company based in China, has announced that it has secured another clinical trial approval from the National Medical Products Administration (NMPA) for its investigational drug HSK42360. This BRAF V600 inhibitor is now poised to be evaluated in clinical trials for…
-
Haisco Pharmaceutical Gets NMPA Green Light for HSK31858 COPD Trial
•
Haisco Pharmaceutical Group Co., Ltd (SHE: 002653), a Chinese pharmaceutical company, has announced that it has received additional clinical trial approval from the National Medical Products Administration (NMPA) for its investigational drug HSK31858. The drug, a reversible dipeptidyl peptidase 1 (DPP1) inhibitor, is now approved for assessment in chronic obstructive…
-
Haisco Pharmaceutical Gets NMPA Greenlight for HSK39775 Solid Tumor Drug Candidate
•
Haisco Pharmaceutical Group Co., Ltd (SHE: 002653), a Chinese pharmaceutical company, has announced that it has received clinical trial approval from the National Medical Products Administration (NMPA) for its innovative drug candidate HSK39775, intended for the treatment of advanced solid tumors. Preclinical study results have demonstrated HSK39775’s potential efficacy across…
-
Chiesi Farmaceutici Acquires Global Rights to Haisco Pharmaceutical’s HSK31858 for Respiratory Diseases
•
Italy-based Chiesi Farmaceutici S.p.A has announced a licensing agreement with China-based Haisco Pharmaceutical Group Co., Ltd (SHE: 002653), acquiring rights to the latter’s reversible dipeptidyl peptidase 1 (DPP1) inhibitor, HSK31858, for respiratory diseases. Chiesi will assume development, manufacturing, and commercial rights to the molecule in markets outside Greater China, excluding…
-
Haisco Pharmaceutical’s HSK21542 Accepted for NMPA Review in Postoperative Pain Management
•
China-based Haisco Pharmaceutical Group Co., Ltd (SHE: 002653) has announced that its clinical trial filing for HSK21542, a Category 1 drug, in postoperative analgesia for abdominal surgery has been accepted for review by the National Medical Products Administration (NMPA). This marks a significant step forward in the development of HSK21542,…
-
Haisco Pharmaceutical’s HSK16149 for Post-Herpes Neuralgia Accepted for NMPA Review
•
China-based Haisco Pharmaceutical Group Co., Ltd (SHE: 002653) has announced that the National Medical Products Administration (NMPA) has accepted for review a market approval filing for its drug candidate HSK16149 as a treatment for post-herpes neuralgia (PHN). This in-house Category 1 drug, an oral gamma-aminobutyric acid (GABA) analogue, is under…
-
Haisco Pharmaceutical Gets NMPA Approval for HSK21542 Chronic Pruritus Clinical Study
•
China-based Haisco Pharmaceutical Group Co., Ltd (SHE: 002653) has announced that it has received approval from the National Medical Products Administration (NMPA) to conduct a clinical study for its Category 1 drug HSK21542, aimed at treating chronic pruritus. Understanding the Impact of Chronic PruritusPruritus, or itching, is an unpleasant sensation…
-
Haisco Pharmaceutical’s HSK31679 Receives Clinical Trial Approval for NASH Treatment
•
China-based Haisco Pharmaceutical Group Co., Ltd (SHE: 002653) has announced that its in-house developed Category 1 drug candidate, HSK31679, has obtained clinical trial approval for the treatment of non-alcoholic steatohepatitis (NASH). HSK31679: A Selective THR-β Agonist for Lipid MetabolismHSK31679 is a highly selective thyroid hormone β receptor (THR-β) agonist that…
-
Haisco Pharmaceutical Gets CDE Approval for HSK38008 Prostate Cancer Clinical Study
•
Haisco Pharmaceutical Group Co., Ltd (SHE: 002653) has announced receiving approval from the Center for Drug Evaluation (CDE) to conduct a clinical study for its Category 1 chemical drug, HSK38008 oral preparation, in the treatment of prostate cancer. HSK38008: An Androgen Mutant AR-V7 Oral Degradation AgentHSK38008 is an androgen mutant…
-
Haisco Pharmaceutical’s EGFR-PROTAC HSK40118 Gains NMPA Approval for Clinical Trials
•
China-based Haisco Pharmaceutical Group Co., Ltd (SHE: 002653) has announced that it has received clinical trial approval from the National Medical Products Administration (NMPA) for its oral small molecule EGFR-PROTAC, HSK40118. The drug is targeted for the treatment of advanced non-small cell lung cancer (NSCLC). Drug Mechanism and Pre-Clinical ResultsHSK40118…
-
Haisco Pharmaceutical Announces Public Offering for Clinical Studies
•
China-based Haisco Pharmaceutical Group Co., Ltd (SHE: 002653) is set to make another public offering of 40 million shares, priced at RMB 20 (USD 2.95) per share, to the Shenzhen Stock Exchange. This move aims to raise significant capital for the company’s ongoing drug development initiatives. Use of ProceedsThe proceeds…
